Abrocitinib

67 interactions 47 explained in plain English 118 cited references

Also sold as: Cibinqo Cibinqo®

About Abrocitinib

Abrocitinib is used to treat moderate to severe eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 12 years of age and older who cannot use other medications for their condition or whose eczema has not responded to other… Read the full Abrocitinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Cangrelor Abciximab Anagrelide Clopidogrel Aspirin Cilostazol

19 Contraindicated 46 Major 2 Moderate

All (67) Contraindicated (19) Major (46) Moderate (2)

Contraindicated

Abrocitinib Abciximab Explained Increased risk of bleeding Details Abrocitinib Anagrelide Agrylin Increased risk of bleeding Details Abrocitinib Aspirin Acuprin® Explained Increased risk of bleeding Details Abrocitinib Cangrelor Kengreal Explained Increased risk of bleeding Details Abrocitinib Cilostazol Pletal® Explained Increased risk of bleeding Details Abrocitinib Clopidogrel Plavix Increased risk of bleeding Details Abrocitinib Dipyridamole Permole® Increased risk of bleeding Details Abrocitinib Epoprostenol Flolan Increased risk of bleeding Details Abrocitinib Eptifibatide Explained Increased risk of bleeding Details Abrocitinib Iloprost Aurlumyn Increased risk of bleeding Details Abrocitinib Prasugrel Effient Explained Increased risk of bleeding Details Abrocitinib Selexipag Uptravi Explained Increased risk of bleeding Details Abrocitinib Sulfinpyrazone Explained Increased risk of bleeding Details Abrocitinib Ticagrelor Brilinta Explained Increased risk of bleeding Details Abrocitinib Ticlopidine Ticlid® Explained Increased risk of bleeding, and increased abrocitinib and active metabolite exposure Details Abrocitinib Tirofiban Explained Increased risk of bleeding Details Abrocitinib Treprostinil Orenitram Explained Increased risk of bleeding Details Abrocitinib Vorapaxar Zontivity Explained Increased risk of bleeding Details Abrocitinib Aspirin Rectal Aspirin Increased risk of bleeding Details

Major

Abrocitinib Relugolix Orgovyx Explained Increased relugolix exposure Details Abrocitinib Colchicine Colcrys Explained Increased exposure of P-glycoprotein substrate Details Abrocitinib Apalutamide Erleada Explained Decreased abrocitinib and active metabolite exposure Details Abrocitinib Belzutifan Welireg Explained Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Abrocitinib Cannabidiol Epidiolex Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Abrocitinib Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Carbamazepine Carbatrol Explained Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Abrocitinib Clomipramine Anafranil Explained Increased clomiPRAMINE exposure Details Abrocitinib Cyclosporine Atopica Explained Increased exposure of P-glycoprotein substrate Details Abrocitinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Abrocitinib Deutivacaftor Explained Increased CYP2C9 substrate exposure Details Abrocitinib Digoxin Cardoxin® Increased exposure of P-glycoprotein substrate Details Abrocitinib Doxifluridine Explained Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Abrocitinib Doxorubicin Hydrochloride Liposome Explained Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Abrocitinib Ensartinib Explained Increased ensartinib exposure Details Abrocitinib Everolimus Afinitor Increased exposure of P-glycoprotein substrate Details Abrocitinib Fluconazole Diflucan Explained Increased abrocitinib exposure and an increased active metabolite exposure Details Abrocitinib Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Abrocitinib Fluvoxamine Explained Increased abrocitinib and active metabolite exposure Details Abrocitinib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.